Breaking News

Advion BioServices Expands Biomarker Group

Advion BioServices, Inc. has expanded its LC/MS Biomarker Services Group in response to increased interest in the use of biomarkers in drug development.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Advion BioServices, Inc. has expanded its LC/MS Biomarker Services Group in response to increased interest in the use of biomarkers in drug development. The company will assign an increased commitment of staffing, Thermo Scientific and Applied Biosystems mass spectrometers, liquid chromatography and automated liquid handling systems to this service. Advion launched its LC/MS Biomarker Services Group in 2008.

“Expansion of our LC/MS Biomarker Services Group reflects an increasing demand for biomarker methods as companion assays to other bioanalytical approaches needed for the development of new drugs,” says Dr. Stephen Lowes, Advion BioServices’ senior vice president, Science. “The FDA has acknowledged that biomarkers can help pharmaceutical companies streamline expensive, later-phase clinical trials by using fewer subjects or patients. Our extensive experience with mass spectrometry, immunoassays, and sample management means that we can meet the need for rapid biomarker assay development, validation, and sample analysis.”

Under the direction of Dr. Lowes, the group is led by Dr. Gary Schultz, senior director, biomarkers, who has played a key role in developing new tools and methods for biomarker analysis including the ESI Chip, TriVersa NanoMate, and RePlay proteomics system.

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters